Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AXGN 
Axogen Inc (AXGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: AXGN (4-star) is a STRONG-BUY. BUY since 15 days. Simulated Profits (5.71%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.56
1 Year Target Price $36.56
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 219.08% | Avg. Invested days 36 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.54B USD | Price to earnings Ratio - | 1Y Target Price 36.56 |
Price to earnings Ratio - | 1Y Target Price 36.56 | ||
Volume (30-day avg) 7 | Beta 1 | 52 Weeks Range 9.22 - 34.71 | Updated Date 01/9/2026 |
52 Weeks Range 9.22 - 34.71 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.98% | Operating Margin (TTM) 3.18% |
Management Effectiveness
Return on Assets (TTM) 1.21% | Return on Equity (TTM) -1.91% |
Valuation
Trailing PE - | Forward PE 82.64 | Enterprise Value 1551852422 | Price to Sales(TTM) 7.17 |
Enterprise Value 1551852422 | Price to Sales(TTM) 7.17 | ||
Enterprise Value to Revenue 7.23 | Enterprise Value to EBITDA 118.06 | Shares Outstanding 46122289 | Shares Floating 45109905 |
Shares Outstanding 46122289 | Shares Floating 45109905 | ||
Percent Insiders 2.79 | Percent Institutions 92.52 |
Upturn AI SWOT
Axogen Inc
Company Overview
History and Background
AxoGen Inc. was founded in 1995 with the goal of developing innovative solutions for peripheral nerve repair. Key milestones include FDA approval for its Avanceu00ae Nerve Graft in 2007, and subsequent expansions into various surgical specialties. The company has evolved to become a leader in the field of regenerative medicine for nerve injuries, focusing on both surgical and non-surgical interventions.
Core Business Areas
- Peripheral Nerve Repair Solutions: AxoGen develops and markets advanced solutions for the surgical repair of peripheral nerve damage. This includes nerve grafts and conduits designed to facilitate nerve regeneration following injury, disease, or surgical resection.
- Regenerative Medicine Technologies: The company's platform technologies are rooted in biological principles to promote nerve healing and functional recovery. This encompasses both their proprietary nerve grafts and other related regenerative treatments.
Leadership and Structure
AxoGen's leadership team is comprised of experienced professionals in the medical device and life sciences industries. The company operates with a functional organizational structure, with departments dedicated to research and development, manufacturing, sales and marketing, and clinical affairs. Specific leadership roles and a detailed organizational chart are typically available on the company's investor relations website.
Top Products and Market Share
Key Offerings
- Avanceu00ae Nerve Graft: A key product, the Avanceu00ae Nerve Graft is a decellularized, off-the-shelf allograft nerve graft used for the surgical repair of peripheral nerve injuries. It aims to provide a biological scaffold for nerve regeneration. Market share data for specific products is proprietary, but AxoGen is a significant player in the peripheral nerve repair market. Competitors include companies offering synthetic conduits or other biological grafts. Direct revenue figures for this product are not publicly disclosed separately.
- AxoGuardu00ae Nerve Connector: Designed to bridge nerve gaps and facilitate coaxial alignment of nerve endings for surgical repair. Like the Avanceu00ae Nerve Graft, specific market share and revenue data are not publicly itemized. Competitors include other nerve coaptation devices and surgical techniques.
- Renuvionu00ae (formerly J-Plasmau00ae): While not a direct nerve repair product, AxoGen has marketing and distribution agreements for Renuvionu00ae, a device used for tissue tightening and contouring in cosmetic and reconstructive surgery. This represents a diversification strategy. Its market position and competitors are within the aesthetic medicine and energy-based device markets.
Market Dynamics
Industry Overview
AxoGen operates within the broader medical device and regenerative medicine sectors, specifically focusing on the peripheral nerve repair market. This market is driven by an increasing incidence of nerve injuries due to trauma, surgery, and chronic conditions, coupled with advancements in biomaterials and surgical techniques. The demand for minimally invasive and effective treatment options is a key trend.
Positioning
AxoGen is positioned as a leader in the surgical repair of peripheral nerve injuries, offering an alternative to autograft and synthetic options. Its key competitive advantages include its proprietary Avanceu00ae Nerve Graft, which is an off-the-shelf allograft, reducing the need for nerve harvesting from elsewhere in the patient's body. The company also benefits from a dedicated sales force focused on educating surgeons about their technologies.
Total Addressable Market (TAM)
The total addressable market for peripheral nerve repair is substantial, estimated to be in the billions of dollars globally, driven by the prevalence of nerve injuries. AxoGen is positioned to capture a significant portion of this market with its innovative solutions, though it faces competition from established medical device companies and alternative treatment modalities.
Upturn SWOT Analysis
Strengths
- Proprietary allograft technology (Avanceu00ae Nerve Graft)
- First-mover advantage in off-the-shelf allograft nerve repair
- Strong focus on a specialized medical niche
- Growing surgeon adoption and education programs
- Potential for expanding product indications and applications
Weaknesses
- High cost of products can be a barrier for some healthcare systems
- Reliance on surgical procedures, which can be cyclical
- Limited product diversification outside of nerve repair (excluding Renuvionu00ae distribution)
- Profitability challenges due to significant R&D and sales & marketing expenses
- Dependence on regulatory approvals and reimbursement policies
Opportunities
- Expansion into international markets
- Development of new nerve regeneration technologies
- Strategic partnerships and collaborations
- Increased awareness and demand for nerve repair solutions
- Leveraging Renuvionu00ae to diversify revenue streams
Threats
- Competition from synthetic nerve conduits and autograft procedures
- Changes in healthcare reimbursement policies
- Adverse regulatory changes or product recalls
- Economic downturns impacting elective surgical procedures
- Emergence of disruptive technologies in regenerative medicine
Competitors and Market Share
Key Competitors
- Integra LifeSciences Holdings Corporation (IART)
- Stryker Corporation (SYK)
- Boston Scientific Corporation (BSX)
Competitive Landscape
AxoGen's advantages lie in its specialized focus on peripheral nerve repair and its proprietary allograft technology, offering a unique solution compared to synthetic alternatives or the need for autografts. However, larger competitors like Integra LifeSciences and Stryker have broader product portfolios, greater financial resources, and established distribution channels, which can pose a challenge. Boston Scientific, while not directly competing in all areas, has a strong presence in related surgical markets.
Growth Trajectory and Initiatives
Historical Growth: AxoGen has demonstrated historical revenue growth, driven by increasing surgeon adoption and market penetration for its Avanceu00ae Nerve Graft. This growth has been fueled by investments in building a specialized sales force and expanding its product portfolio.
Future Projections: Future growth projections for AxoGen are contingent on continued market adoption, successful new product development, expansion into new geographic regions, and favorable reimbursement environments. Analyst estimates for future revenue and EPS can be found in financial reports and analyst research.
Recent Initiatives: Recent initiatives have included efforts to expand the commercial team, focus on key surgical specialties, and potentially explore new indications for their nerve repair technologies. The distribution agreement for Renuvionu00ae also represents a strategic initiative to broaden its revenue base.
Summary
AxoGen Inc. is a specialized player in the peripheral nerve repair market with a strong, proprietary allograft technology. Its core strength lies in its innovative Avanceu00ae Nerve Graft, positioning it as a leader in a growing niche. However, the company faces challenges related to high product costs, historical unprofitability due to aggressive investment in sales and marketing, and competition from larger, more diversified medical device companies. Continued growth will depend on expanding surgeon adoption, achieving greater market penetration, and navigating reimbursement landscapes while potentially diversifying revenue streams.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AxoGen Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Research Reports
- Financial News Outlets
Disclaimers:
This JSON output is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Market share data is estimated and may not reflect precise current figures. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axogen Inc
Exchange NASDAQ | Headquaters Alachua, FL, United States | ||
IPO Launch date 1990-03-27 | President, CEO & Director Mr. Michael D. Dale | ||
Sector Healthcare | Industry Medical Devices | Full time employees 451 | Website https://www.axogeninc.com |
Full time employees 451 | Website https://www.axogeninc.com | ||
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.